Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated ...
Adding Kisqali (ribociclib) to a nonsteroidal aromatase inhibitor helped patients with hormone receptor–positive, HER2-negative early breast cancer live longer without their disease returning, ...
Researchers appear to have found a solution for breast cancer patients who do not respond well enough to the common treatment ...
The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...
She emphasized that while elacestrant has properties similar to other agents, imlunestrant is closer to a “pure” ER ...
The "CD47 Inhibitors Drug Market Opportunity, Clinical Application by Indications & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
Researchers at Baylor College of Medicine have developed a powerful new data analysis method named COOKIE-Pro (Covalent Occupancy Kinetic Enrichment via Proteomics) that provides a comprehensive, ...
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback